Department for Rheumatology,
1 Laboratory for Clinical Chemistry, Medisch Spectrum Twente, Enschede, The Netherlands
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Objective. To compare the effects of the COX-2-selective inhibitor, meloxicam, with those of the non-selective NSAID, naproxen, on platelet function and thromboxane levels in RA patients.
Methods. In this randomized, controlled, cross-over trial, 10 RA patients used meloxicam 7.5 mg bid and naproxen 500 mg bid, each during a 2-week period. Washout periods were applied. Before and after each 2-week period of NSAID intake, laboratory studies were performed.
Results. Platelet aggregation was significantly less influenced, thromboxane levels were less inhibited (246 vs 117 pg/ml) and bleeding times were less prolonged with meloxicam than with naproxen (3.2 vs 2.3 min). Moreover, the results of all tests during meloxicam exposure were comparable with baseline values.
Conclusion. In RA patients, meloxicam, a representative of the selective COX-2 inhibitors, does not interfere with platelet function and thromboxane levels, in contrast with naproxen (a non-selective COX inhibitor).
KEY WORDS: Platelet aggregation, Thromboxane, Bleeding time, Non-steroidal anti-inflammatory drugs, Rheumatoid arthritis, Meloxicam, Naproxen.
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Many studies have focused on the more favourable gastrointestinal tolerance of COX-2-specific and -selective inhibitors compared with the classic, non-selective NSAIDs [4]. However, data concerning the side-effects on platelet aggregation are scarce. Classical NSAIDs have definite effects on platelet aggregation through inhibition of COX-1 [5], the unique iso-enzyme for the formation of thromboxane. In accordance with the results of former studies in healthy volunteers [6, 7], we recently demonstrated in patients with rheumatoid arthritis (RA), that nabumetone (a more selective COX-2 inhibitor) did not interfere with platelet aggregation to the same extent as naproxen (a non-specific NSAID) [8]. In this study, thromboxane concentrations were not analysed. Other clinical studies with patients, obviously different from healthy volunteers, are lacking.
The goal of the present study was to compare the effects of another selective COX-2 inhibitor (meloxicam) with naproxen on platelet function, thromboxane levels, and bleeding time in patients with RA.
![]() |
Patients and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
This randomized cross-over study comprised four 2-week periods (see Fig. 1). In the second and fourth periods, both following a 2-week washout of all NSAIDs, study medication was prescribed. The patients were randomized to either naproxen 500 mg bid or meloxicam 7.5 mg bid in the second period. The alternative NSAID was prescribed in the fourth period. After each period a platelet count, platelet aggregation studies, bleeding time tests, and thromboxane measurements were performed; in addition, activated partial thromboplastin time (aPTT) and prothrombin time (PT) measurements were carried out at the start of the study.
|
For the platelet aggregation studies, platelet-rich plasma (PRP) was obtained by centrifugation of citrated blood at 200 g for 10 min and platelet-poor plasma (PPP) was obtained by centrifugation at 1850 g for 15 min at room temperature. The platelet concentration in the PRP was diluted to approximately 250x109/l using PPP. The platelet aggregation studies were performed according to Born's method [12] at 37°C using a PAP-4 aggregometer (Meyvis, Bio Data Corp, USA). During the experiment, optical density was continuously recorded. The 0 and 100% aggregation levels were set with PRP and PPP, respectively. When a stable baseline was obtained with 450 µl of PRP, 50 µl of one of the aggregation-inducing agents was added. The final concentrations in the reaction vessel were: 2.5 and 5.0 µM adenosine diphosphate (ADP), 1.0 and 5.0 µM epinephrine, 1.0 and 4.0 mg/l collagen, 0.6 and 1.2 g/l ristocetin and 500 mg/l arachidonic acid. The maximum height and slope of the aggregation curves were determined (see Fig. 2) and the type of curve was described: biphasic, monophasic, or non-sustained.
|
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
At baseline, after the first washout, platelet counts, aPTT, PT and bleeding time tests were normal.
In general, the influence of naproxen on platelet aggregation exceeded the influence of meloxicam, except when aggregation was induced by ristocetin (Table 1). Similar results were obtained considering the changes in the slope of the aggregation curve after induction by epinephrine 5.0 µM, collagen and arachidonic acid (P=0.01; data not shown). Disappearance of secondary aggregation, as observed by a monophasic (instead of biphasic) type of aggregation curve in tests with epinephrine, was more often demonstrated after the use of naproxen than after meloxicam (in 5/10 and 1/10 patients, respectively). Disaggregation, as observed by a non-sustained type of aggregation curve in tests with ADP, occurred more frequently after the use of naproxen than after meloxicam (in 7/10 and 1/10 patients, respectively).
|
Baseline thromboxane-B2 levels were 228 (130310) pg/ml, changing to 246 (150350) pg/ml after 2 weeks of meloxicam and to 117 (70140) pg/ml after 2 weeks of naproxen (P=0.41 vs P=0.01, respectively, for comparison with baseline values).
The results of the aggregation tests (except when induced by ristocetin) correlated highly with the thromboxane measurements: correlation coefficients (r) between 0.59 and 0.80, with P<0.01. The changes in bleeding time correlated with those in thromboxane levels (r=-0.48; P<0.05) and with the changes in platelet aggregation, when stimulated by epinephrine (both concentrations; r=-0.49 and -0.52; P<0.05) and arachidonic acid (r=-0.56; P<0.01).
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Naproxen and meloxicam have comparable plasma half-lives (15 and 20 h, respectively) and both reach steady-state plasma levels in about 75100 h, i.e. 4 days. Hence, the influence of the time of NSAID intake on the various laboratory tests (performed after 14 days) can be considered minimal.
Platelet aggregation can be studied by using inductors like ADP, epinephrine, collagen, arachidonic acid and ristocetin; all, except the latter (which is used as a control test for other bleeding conditions), are dependent on COX-1. So, with COX-1 inhibition (e.g. by NSAIDs), platelet aggregation will progress slower (with a less steep slope of the curve), and reach a smaller maximum (and sometimes even disaggregation); moreover, secondary aggregation will not take place. The data of this study unequivocally show significant differences in the inhibition of the COX-1-dependent tests after using meloxicam as compared with naproxen.
Two weeks of naproxen significantly reduced thromboxane-B2 levels, whereas 2 weeks of meloxicam left them unchanged. These differences in thromboxane-B2 levels correlated well with the results of the platelet aggregation tests, which has never been reported. Hitherto, only our own, former, study investigated the changes in platelet aggregation after the use of non-selective vs COX-2-selective NSAIDs in patients, but without thromboxane measurements [8]; all other studies were carried out in healthy volunteers [6, 1519].
Bleeding time is influenced by platelet aggregation, but also by numerous other factors, such as the test method, skin depth, age, gender, underlying diseases and medication. As a result, studies on the influence of NSAIDs on bleeding time in healthy volunteers show conflicting results. In the present study, bleeding times increased significantly during the use of naproxen as compared with meloxicam. The differences in bleeding time correlated with the changes in both platelet aggregation and thromboxane concentration.
In conclusion, we have demonstrated that in RA patients, meloxicam, a representative of selective COX-2 inhibitors, has negligible effects on platelet function, as measured by bleeding time, aggregation studies and thromboxane-B2 measurements.
![]() |
Acknowledgments |
---|
![]() |
Notes |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|